TURALIO Risk Evaluation and Mitigation Strategy Program: 6-year retrospective hepatic safety assessment
Year: 2026
Type: article
Study design: Observational Study
Abstract: Aims: Risk Evaluation and Mitigation Strategy (tREMS) Program. Methods: Retrospective hepatic safety data (08/2019-08/2025) were collected from healthcare professionals and patients in the tREMS Program. Results: During the current reporting period (06/2024-08/2025), 133/145 (91.7%) new patients received ≥1 pexidartinib dispense. For the cumulative 6-year reporting period, 878/929 (94.5%) patients received ≥1 pexidartinib dispense. Overall, 51/878 (5.8%) patients had adverse events or laboratory abnormalities suggesting serious and potentially fatal liver injury; of these, 47 (92.2%) discontinued pexidartinib, 3 (5.9%) interrupted doses, and 1 (2.0%) continued at the same dose. By August 2025, 34 (66.7%) events were fully resolved, 6 (11.8%) were resolving, 9 (17.6%) were unresolved, and 2 (3.9%) had unknown outcomes. There were no cases of irreversible liver injury, additional cases of vanishing bile duct syndrome, or new safety signals during the current reporting period. Conclusions: The tREMS Program effectively mitigates hepatotoxicity risk through prompt intervention/reporting and timely dose modifications for adverse event management. When used according to guidelines, pexidartinib is a therapeutic option for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
Source: Patient Related Outcome Measures
Institution: Daiichi Sankyo (United States)
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,320
OpenAlex ID: W7225308618
